Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Bariatric surgery in obese individuals leads to rapid and lasting remission of type 2 diabetes (T2D). This phenomenon occurs independently of weight loss possibly via a combination of factors. The incretin hormone GLP-1 has so far been recognised as a critical factor. However, recent data have indicated that elevation in another gut hormone, peptide tyrosine tyrosine (PYY), may drive the beneficial effects of surgery. Here we discuss recent findings on PYY-mediated control of glucose homeostasis and its role in diabetes, in the context of what is known for GLP-1. Identification of factors that increase the expression of PYY following bariatric surgery and elucidation of its role in diabetes reversal may have clinical relevance as a nonsurgical therapy for T2D.

Original publication

DOI

10.1016/j.tem.2017.04.005

Type

Journal article

Journal

Trends Endocrinol Metab

Publication Date

08/2017

Volume

28

Pages

626 - 636

Keywords

bariatric surgery, diabetes, incretins, peptide tyrosine tyrosine (PYY), Animals, Bariatric Surgery, Diabetes Mellitus, Type 2, Gastrointestinal Hormones, Glucose, Homeostasis, Humans, Islets of Langerhans, Peptide YY